Navigation Links
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Date:10/27/2008

SEATTLE, Oct. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced positive data from a Phase 1/2a study demonstrating that repeat administration with TRU-015 continues to produce persistent responses and significant improvements in rheumatoid arthritis (RA) signs and symptoms based on American College of Rheumatology (ACR) criteria. Trubion also announced positive results following preliminary analyses from a Phase 2b study in which patients have received one course of re-treatment with 800 mg of TRU-015. TRU-015 is being developed by Wyeth Pharmaceuticals in collaboration with Trubion.

TRU-015 Phase 1/2a Re-treatment Data: Re-treatment Administered Every 24 Weeks for 2 Years Produces Well-Tolerated and Consistent Results

Re-treatment data from the Phase 1/2a study (15001) were presented on Oct. 26, 2008, in a poster session at the ACR 2008 Annual Meeting in San Francisco. Patients treated with a single course of TRU-015 at 5 mg/kg or higher in a previously conducted Phase 1/2a study (15001) were eligible for re-treatment. Patients given an initial dose of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment and those given higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. Patients were eligible for repeat therapy at 24-week intervals.

Thirty-eight patients entered the Phase 1/2a re-treatment study; some patients have received as many as seven courses of TRU-015 at the time of this assessment. At 24 weeks, ACR 20, 50 and 70 response rates for 18 patients that have received their third re-treatment with 5 mg/kg or 15 mg/kg TRU-015 were 50%, 17% and 11%, respectively. Ongoing patient evaluations demonstrated maintenance of ACR responses foll
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
2. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
3. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
4. Trubion Announces Presentations at April/May Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
10. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
11. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014   ...   Elsevier , a world-leading provider of ... to announce the launch of the latest title in the ... Opinion in Food Science . ... with a new platform to keep up-to-date with the expanding ...
(Date:11/24/2014)... Billerica, Massachusetts (PRWEB) November 24, 2014 ... Simplify Panels ” from METTLER TOLEDO demonstrates how ... panel. , Power analytics and sample panel design ... control cycle chemistry and protect against corrosion and ... take up a significant amount of panel space. ...
(Date:11/22/2014)... November 21, 2014 During his lifetime ... the need to surround himself with great people and ... entrepreneur, his friends often marveled at his extraordinarily courageous ... his life and -- even with his death impending—that’s ... Alzheimer’s disease that would ultimately take his life. , ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market ... (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... to 2018” analyses and studies the major market ... Europe, Asia, and Rest of the World. , ... spread through 135 pages and in-depth TOC on ...
Breaking Biology Technology:Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... Corporation,(NYSE: POL ), a premier provider of ... it has entered into an exclusive,license arrangement for ... Battelle., The global market for plasticizers is ... consumed in vinyl-based formulations.,Specialty plasticizers currently account for ...
... Quarter 2007, EMERYVILLE, Calif., Aug. 5 Onyx,Pharmaceuticals, ... results,for the three and six months ended June 30, ... per diluted share, for the second quarter of 2008,compared ... per diluted share, in the,same period in 2007. Excluding ...
... - Atrium Innovations Inc.,(TSX: ATB), a recognized leading ... products for the health and,nutrition industries, today announced ... Fitzgibbon, will present a company overview,at the upcoming ... August 12, 2008 at 11 am (eastern time), ...
Cached Biology Technology:PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... ever European-wide retrospective analysis presented today at the International ... to be effective treatments, providing positive survival rates in ... , Wilson disease is a rare genetic storage disorder ... effectively, leading to excess copper build up, liver failure ...
... investigation of the Tigris-Euphrates delta in 20 years was ... explore the links between wetland resources and the emergence ... in Iraq stopped in the 1990s," said Carrie Hritz, ... but because their work is unpublished, we are unsure ...
... Davis cancer researchers have found that older men with ... CT scans over lymph node removal are at greater ... week in the journal Cancer, indicate that physicians should ... discussing treatment options with their patients. Along ...
Cached Biology News:European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease 2Archaeologists explore Iraqi marshes for origins of urbanization 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3
... Error-free cloning of BAC (100+kb), fosmid (40kb), ... insert stability than any othe BAC vector. ... high yields and easy recombinant DNA purification. ... transcription-free (pSMART VC) vectors for the highest ...
...
... Adapted to Sf-900 ... were isolated from Spodoptera ... insect cells (1). The ... to serum-free suspension culture ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: